Generic Name and Formulations:
Sodium hyaluronate 5000 23mg/mL; viscoelastic soln for intraocular use.
Indications for HEALON5:
Inject through a fine cannula into the eye. Amount varies depending on surgery, repeated inj may be required. One syringe of 0.6mL is usually sufficient in anterior segment surgery.
Single use only; reuse may cause inflammatory reaction. Glaucoma; consider prophylactic pressure-lowering treatment. Complete removal of soln necessary to avoid intraocular pressure peaks post-op.
Incompatibility, resulting in opalescence, between sodium hyaluronate and solutions containing quaternary ammonium ions (eg, detergents, benzalkonium chloride).
Ophthalmic viscosurgical device.
Transient rise in intraocular pressure, myopic shift (if product not completely removed).
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- AMA: Federal Government Must Tackle Rising Insulin Prices
- Diabetes Medication Reconciliation May Reduce Risk of ED Visits